Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-03-28
2006-03-28
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S026200, C536S026230, C536S026260, C514S045000, C514S046000, C514S047000, C514S050000, C514S051000
Reexamination Certificate
active
07018985
ABSTRACT:
The present invention provides novel compounds of dinucleotide polyphosphates and the method of preventing or treating diseases or conditions associated with platelet aggregation. The method comprises administering systemically to a patient a pharmaceutical comprising a purinergic P2τreceptor antagonist, in an amount effective to elevate its extracellular concentration to bind to P2τreceptors and inhibit P2τreceptor-mediated platelet aggregation. Methods of systemic administration include injection by intravenous, intramuscular, intrasternal and intravitreal routes, infusion, transdermal administration, oral administration, rectal administration and intra-operative instillation.
REFERENCES:
patent: 4621076 (1986-11-01), Kuzuya et al.
patent: 5049550 (1991-09-01), Zamecnik
patent: 5292498 (1994-03-01), Boucher
patent: 5596088 (1997-01-01), Boucher et al.
patent: 5607836 (1997-03-01), Boucher et al.
patent: 5628984 (1997-05-01), Boucher
patent: 5635160 (1997-06-01), Stutts et al.
patent: 5654285 (1997-08-01), Ingall et al.
patent: 5656256 (1997-08-01), Boucher et al.
patent: 5681823 (1997-10-01), Kim et al.
patent: 5691156 (1997-11-01), Boucher et al.
patent: 5721219 (1998-02-01), Ingall et al.
patent: 5747496 (1998-05-01), Cox et al.
patent: 5763447 (1998-06-01), Jacobus et al.
patent: 5789391 (1998-08-01), Jacobus et al.
patent: 5837861 (1998-11-01), Pendergast et al.
patent: 5900407 (1999-05-01), Yerxa et al.
patent: 5902567 (1999-05-01), Boucher
patent: 5935555 (1999-08-01), Stutts et al.
patent: 5955447 (1999-09-01), Ingall et al.
patent: 5958897 (1999-09-01), Jacobus et al.
patent: 5962432 (1999-10-01), LaCroix et al.
patent: 5968913 (1999-10-01), LaCroix et al.
patent: 5972904 (1999-10-01), Jacobus et al.
patent: 5981506 (1999-11-01), Jacobus et al.
patent: 6022527 (2000-02-01), Boucher et al.
patent: 6037343 (2000-03-01), Ali
patent: 6040317 (2000-03-01), Duggan et al.
patent: 6133247 (2000-10-01), Boucher et al.
patent: 6143279 (2000-11-01), Boucher et al.
patent: 6159952 (2000-12-01), Shaffer et al.
patent: 6166022 (2000-12-01), Brown et al.
patent: 6323187 (2001-11-01), Yerxa et al.
patent: 6528640 (2003-03-01), Beigelman
patent: 1407903 (1995-10-01), None
patent: WO 89/04321 (1989-05-01), None
patent: WO 92/01673 (1991-07-01), None
patent: WO 92/17488 (1992-10-01), None
patent: WO 94/08593 (1994-04-01), None
patent: WO 94/18216 (1994-08-01), None
patent: WO 95/10538 (1995-04-01), None
patent: WO 97/03084 (1997-01-01), None
patent: WO 97/29456 (1997-08-01), None
patent: WO 97/35591 (1997-10-01), None
patent: WO 98/03177 (1998-01-01), None
patent: WO 98/03182 (1998-01-01), None
patent: WO 98/15835 (1998-04-01), None
patent: WO 98/19685 (1998-05-01), None
patent: WO 98/28300 (1998-07-01), None
patent: WO 98/34593 (1998-08-01), None
patent: WO 98/34942 (1998-08-01), None
patent: WO 99/01138 (1999-01-01), None
patent: WO 99/05155 (1999-02-01), None
patent: WO 99/09998 (1999-03-01), None
patent: WO 99/32085 (1999-07-01), None
patent: WO 99/61012 (1999-12-01), None
patent: WO 00/30629 (2000-06-01), None
patent: WO 00/33080 (2000-06-01), None
patent: WO 00/34283 (2000-06-01), None
patent: WO 00/39145 (2000-07-01), None
patent: WO 00/50024 (2000-08-01), None
patent: WO 01/19826 (2001-03-01), None
patent: WO 01/36421 (2001-05-01), None
patent: WO 01/39781 (2001-06-01), None
patent: PCT/US01/41818 (2002-03-01), None
Kim et al., J. Biol. Chem. vol. 269(9), pp. 6471-6477, 1994.
Neuhaus, K. L. et al., “Safety Observations from the Piolet Phase of the Randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) Study,”Circulation90(4): 1638-1642 (1994).
Olivier, K. et al., “Acute Safety and Effects on Mucociliary Clearance of Aerosolized Uridine 5'—Triphosphate + Amiloride in Normal Human Adults,”-Am. J. Respir. Crit. Care Med.154:217-223 (1996).
Quinn, M and Desmond J. Fitzgerald, “Ticlopidine and Clopidogrel,”Circulation100(15):1667-1672 (1999).
Romson, J., et al., “Electrical Induction of Coronary Artery Thrombosis in the Ambulatory Canine: A model for IN VIVO Evaluation of Anti-Throbotic Agents,”Thromb. Res.17:841-853 (1980).
Shebuski, R., et al., “Acceleration of Recombinant Tissue-Type Plasminogen Activator-Induced Thrombolysis and Prevention of Reocclusin by the Combination of Heparin and the Arg-Gly-Asp-Containing Peptide Bitistatin in a Canie Model of Coronary Thrombosis,”Circulation82(1):169-177 (1990).
Tschopp, J.F., et al., “Inhibition of coronary artery reocclusion after thrombolysis with an RGD-containing peptide with no significant effect on bleeding time,”Coron. Artery Dis.4:809-817 (1993).
Weber, M., et al., “Low-Dose Verses for Prevention of Coronary Graft Occlusion,”AnticoagulansAm. J. Cardiol.66:1461-1468 (1990).
Bernat, A., et al., “Effect of Various Antiplatelet Agents on the Acute Arterial Thrombosis in the Rat,”Thromb. Haemostas. (1993) 70(5)812-816.
Bush, L., et al., “Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canie coronary arteries,”Circulation69(5):1161-1170, (1984).
EPIC Investigators, “Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein lib/iiia Receptor in High-Risk Coronary Angioplasty,”New England J. Med.(1994) 330:956-961.
Folts, J. et al., “Platelet Aggregation in Partially Obstructed Vessels and its Elimination with Asprian,”Circulation54(3): 365-370 (1976).
Frederick, L.G., et al., “The Protective Dose of the Potent GPIIb/IIIa Antagonist SC-54701A is Reduced When Used in Combination with Asprian and Heparin in Canie Model of Coronary Artery Thrombosis,”Circulation93(1): 129-134 (1996).
Geiger, J., et al., “Specific impairment of Human Platelet P2Y ac ADP Receptor-Mediated Signaling by the Antiplatelet Drug Clopidogrel,”Arterioscler. Thromb. Vasc. Biol.19:2007-2011.
Gusto lia Investigators, The Global Use of Strategies to Open Occluded Coronary Arties., “Randomized Trial of Intravenous Heprain Versus Recombinant Hirudin for Acute Coronary Syndromes”,Circulation90(4):1631-1637 (1994).
Hass, W. et al., “A Randomized Trial Comparing Ticlopidine Hydrochloride with Asprian for the Prevention of Stroke for High-Risk Patients,”N. Engl. J. Med.321(8):501-507 (1989).
Herbert, J.M. et al., Inhibitory Effect of Clopidogrel on Platelet Adhesion and Intimal Proliferation After Arterial Injury in Rabbits,Arterioscl. Thromb.(1993) 13(8):1171-1179.
Hourani, et al., The Platelet ADP Receptors Meeting, La Thuile, Italy, Mar. 29-31, 2000.
Humphries, R.G. et al., “Pharmacological profile of the novel P25-Purinoceptor antagonist, FPL 67085 in vitro and in the anaesthesized rat in vitro,”Br. J. Pharmacol.115:1110-1116 (1995).
Ingall, A., et al., “Antagonists of the Platelet P2t Receptor: A Novel Approach to Antithrombotic Therapy,”J. Med. Chem.42:213-220 (1999).
Lazarowski, E., et al., “Pharmacological selectivity of the cloned human P2u-purinoceptor: potent activation by diadenosine tetraphosphate,”Brit. J. Pharm.116:1619-1627 (1995).
Lekstkrom, J and William R. Bell, “Asprian in the Prevention of Thrombosis,”Medicine70(3):161-178 (1991).
Maffrand, J.P., et al., “ADP Plays a Key Role in Thrombogenesis in Rats,”Thromb. Haemostas.(1988) 59(2):225-230.
Mickelson, J.K. et al., “Antiplatelet Antibody [7E3 F(ab')2] Prevents Rethrombosis After Recombinant Tissue-Type Plasminogen Activator-Induced Coronary Artery Thrombolysis in a canie Model,”Circulation81(2):617-627 (1990).
Antiplatelet Trialists'Collaboration., “Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of Death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients,”Br. Med. J.308: 81-106 (1994).
Antiplatelet Trialists'Collaboration., “Collaborative overview of randomised trials of antiplatelet-therapy-II: M
Boyer José L.
Douglass, III James G.
Olins Gillian M.
Yerxa Benjamin R.
Howrey LLP
Inspire Pharmaceuticals Inc.
Kung Viola T.
Owens Howard V.
University of North Carolina at Chapel Hill
LandOfFree
Composition and method for inhibiting platelet aggregation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for inhibiting platelet aggregation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for inhibiting platelet aggregation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3588751